DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, whereas the remaining patients displayed monoallelic mutations. TP53-multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53-monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53-monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53-multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q)., V.S. was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC; grant IG-26537-2021). M.D.P. was supported by the Horizon 2020/2023 program of the European Union (GenoMed4All, 101017549; Synthema project, 1101095530); the TRANSCAN 7 Horizon 2020 program (EuroMDS 20180424); European Union–Next Generation EU, NRRP M6C2 (Investment 2.1 Enhancement and strengthening of biomedical research in the NHS [project PNRR-MAD-2022-12376695]); AIRC Foundation for Cancer Research (29483); and 5 × 1000 MYeloid NEoplasms Research Venture AIRC (project, 21267). F.S. was supported by the Instituto de Salud Carlos III (PI20/0053); TRANSCAN (AECC AC 18/000002); the Generalitat de Catalunya (2017 SGR288 and 2021 SGR00560); and the CERCA Programme/Generalitat de Catalunya, Fundación Internacional Josep Carreras. F.B. was supported by the Instituto de Salud Carlos III (grants PI17/00943 and PI20/01274). D.V. was supported by the Instituto de Salud Carlos III (grants PI17/01088 and PI20/00881)., Peer reviewed